Diabetic Foot Ulcer
Conditions
Brief summary
Diabetic foot ulcers (DFUs) are a frequent clinical problem observed in diabetic patients. Properly managed, most can be cured, but many patients needlessly undergo amputations because of improper diagnostic and therapeutic approaches. The purpose of this study is to evaluate the effectiveness of a compounded, anti-infective irrigation therapy to increase the healing rates of diabetic foot ulcers and thereby provide a new therapeutic option for health care providers treating high-risk patients with DFUs regardless if secondary fungal infections are present. Participants diagnosed with diabetes type 1 or 2 and with a documented open diabetic foot ulcer/wound with or without a secondary fungal infection will be included in this prospective, active intervention pilot study. Healing rates will be evaluated every two weeks following the initiation of study therapy up to three months. Participants with diabetic foot ulcers will be treated with a compounded, anti-infective irrigation therapy daily until closure of the ulcer or up to a maximum of 3 months. Participants will be asked to return to clinic every two - four weeks for assessment of the ulcer and compliance with treatment. A sample size of approximately 100 patients is estimated to have 90% power to detect 15% improvement in ulcer healing rates to 45% and 35% compared to historical benchmarks of approximately 30% for ulcers of \<6 months duration and 20% for ulcers ≥6 months duration and/or prior treatment failure, respectively.
Interventions
DRUGvancomycin-tobramycin-itraconazole
Participants with diabetic foot ulcers will be treated with a compounded, anti-infective irrigation therapy daily until closure of the ulcer or up to a maximum of 3 months. This is an irrigating foot bath with a compounded medication of vancomycin-tobramycin-itraconazole. This medication with combined 3/4 gallon of water. Participant will soak foot in solution for 10 minutes per day. Daily until wound is healed for a minimum of 4 weeks and a maximum of 3 months.
Sponsors
Keystone Pharmacy
University of Mississippi Medical Center
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
All participants receive the same intervention.
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Type 1 or Type 2 diabetes mellitus * An open DFU / wound of any size (including those requiring debridement in operation room or clinic setting) with or without a secondary fungal infection * ≥ 18 years of age * Treatment naïve or treatment failure with oral antibiotics to current wound infection
Exclusion criteria
* Patients who present with untreated or on active-treatment for osteomyelitis, exposed bone, or have a life-threatening need of immediate surgery. * Patients who are allergic to any components of the investigated product. * Patients who have ≥ 15 shoe size * Patients who have received IV antibiotics within the past 30 days * Patients with HgbA1C \> 14 * Patients on active cancer treatment * Patients needing re-vascularization of the affected area but did not receive treatment. * Patients diagnosed with HIV/AIDs * Patients unable or unwilling to obtain and wear off-loading footwear
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Healing Rate | 12 weeks | We will be looking at measurements of the wound at the start of the study and at each study visit until the wound is healed, or the study has ended. The wounds are measured with a ruler by the provider seeing the patient at the time of the visit in centimeters. The wounds are also photographed with a ruler in the photograph for size. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Wound Closure | Until the wound is closed up to 12 weeks | Assessing how many patients wounds closed during the study and the time in weeks it took for the patient to close their wound. |
Countries
United States
Contacts
Primary ContactLaura R Vick, MD
Backup ContactKirby Orme, MD
Outcome results
None listed